• Department of Urology, Inner Mongolia People's Hospital, Huhehaote, Inner Mongolia 010017, P. R. China;
LISan-xiang, Email: 2294474817@qq.com
Export PDF Favorites Scan Get Citation

Objective To evaluate the clinical effect of early and deferred intravesical instillation in the treatment of cystitis glandularis after transurethral resection (TUR). Methods We retrospectively analyzed the clinical data of 95 patients with cystitis glandularis during February 2007 to April 2012. Among them, 37 patients underwent the first intravesical instillation within 24 hours after transurethral resection (group A), while the others underwent the same treatment within a week (group B). Then, intravesical instillation in all patients were carried out once every week for 8 weeks, and after that, it was carried out once every month for 5 to 10 months. All the patients were followed up for 12 to 16 months. The cure rate, improvement rate, total effective rate, recurrence rate and incidence of adverse events associated with therapy were observed. Results Recovery rate, improvement rate, side effects were observed in group A and B respectively, and there was no significant difference between the two groups (P>0.05). But there was significant difference in the total effective rate and recurrence rate (P<0.05). Conclusion The first intravesical instillation within 24 hours after transurethral resection in the treatment of cystitis glandularis can improve curative effect and lower recurrence rate, without the increase of side effects.

Citation: LIUJun-feng, TANZhao-hui, LIXing-zhi, CHINing, LISan-xiang. Comparison between the Clinical Outcome of Early and Deferred Intravesical Instillation Therapy in Treating Cystitis Glandularis after Transurethral Resection. West China Medical Journal, 2014, 29(10): 1841-1844. doi: 10.7507/1002-0179.20140561 Copy

  • Previous Article

    Clinical Features Analysis of Elderly Hip Fracture in Leshan Area
  • Next Article

    The Effect of Full Nutritional Management Model on Perioperative Nutritional Status in Patients with Head and Neck Malignancies